Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and
physical aggressiveness, irritability, wandering, and restlessness. These behaviors often
make caring for patients at home very difficult. Trazodone and haldol are two of the most
commonly prescribed drugs for agitation in AD patients. Behavior management, a non drug
approach, has been effective in reducing signs of agitation. Researchers have yet to compare
the effectiveness of drug versus non drug therapy to treat agitation in AD patients and
determine which is the best treatment. The Alzheimer's Disease Cooperative Study, with
funding from the National Institute on Aging, is conducting an agitation treatment program at
21 sites in 16 States. This study will assess which of the above treatments is most
effective.
Trazodone for Sleep Disturbance in Early Alcohol Recovery
Completed
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phase 2
2002-06-01
This study is a randomized, double-blind clinical trial comparing trazodone (Desyrel) and
placebo among sleep-disturbed, alcohol-dependent individuals shortly after discharge from an
inpatient detoxification program. Subjects will undergo a baseline assessment and random
assignment to trazodone or identical placebo for 12 weeks. All persons completing the alcohol
detoxification at Stanley Street Treatment and Resources (SSTAR) will be screened. (SSTAR of
Rhode Island provides detoxification services to non/underinsured persons of Rhode Island.)
Trazodone for Sleep Disturbance in Early Alcohol Recovery
Completed
Rhode Island Hospital
Phase 2
2002-06-01
This study is a randomized, double-blind clinical trial comparing trazodone (Desyrel) and
placebo among sleep-disturbed, alcohol-dependent individuals shortly after discharge from an
inpatient detoxification program. Subjects will undergo a baseline assessment and random
assignment to trazodone or identical placebo for 12 weeks. All persons completing the alcohol
detoxification at Stanley Street Treatment and Resources (SSTAR) will be screened. (SSTAR of
Rhode Island provides detoxification services to non/underinsured persons of Rhode Island.)
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
